Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463 · see citing works

p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development

Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C. J., Sharpe, A. H., Caput, D., Crum, C. P., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,224 · see citing works

p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities

Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,086 · see citing works

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · see citing works

Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers

Kaghad, M., Bonnet, H., Yang, A., Créancier, L., Biscan, J.-C., Valent, A., Minty, A. J., Chalon, P., Lélias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,630 · see citing works

Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms

Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

A cancer family syndrome in twenty-four kindreds.

Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

Srivastava, S. K., Zou, Z., Pirollo, K. F., Blattner, W. A., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,210 · see citing works

Activating Mutations for Transformation by p53 Produce a Gene Product That Forms an hsc70-p53 Complex with an Altered Half-Life

Finlay, C. A., Hinds, P. W., Tan, T., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144 · see citing works

Post‐translational modifications and activation of p53 by genotoxic stresses

Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,071 · see citing works

p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours

Yang, A., Walker, N., Bronson, R. T., Kaghad, M., Oosterwegel, M. A., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A. H., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 989 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage

Flores, E. R., Tsai, K. Y., Crowley, D. G., Sengupta, S., Yang, A., McKeon, F., & Jacks, T. (2002) · Nature · doi:10.1038/416560a · Cited by 801 · see citing works

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669 · see citing works

Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

Hinds, P. W., Finlay, C. A., & Levine, A. J. (1989) · Journal of Virology · doi:10.1128/jvi.63.2.739-746.1989 · Cited by 595 · see citing works

Wild-type p53 activates transcription in vitro

Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579 · see citing works

Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms

Jeffrey, P. D., Gorina, S. S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 548 · see citing works

Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

Harvey, M., McArthur, M. J., Montgomery, C. A., Butel, J. S., Bradley, A., & Donehower, L. A. (1993) · Nature Genetics · doi:10.1038/ng1193-225 · Cited by 542 · see citing works

Genetic Mechanisms of Tumor Suppression by the Human p53 Gene

Chen, P., Chen, Y., Bookstein, R., & Lee, W. (1990) · Science · doi:10.1126/science.2274789 · Cited by 518 · see citing works

Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Bártek, J., Bártková, J., Vojtěšek, B., Stašková, Z., Lukáš, J., Rejthar, A., Kovařík, J., Midgley, C. A., Gannon, J., & Lane, D. P. (1991) · PubMed · Cited by 506 · see citing works

THE TUMOR SUPPRESSOR GENES

Levine, A. J. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.003203 · Cited by 506 · see citing works

Untitled work

(1993) · PubMed · Cited by 469 · see citing works

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464 · see citing works

p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417 · see citing works

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408 · see citing works

Rhabdomyosarcoma in Children: Epidemiologic Study and Identification of a Familial Caneer Syndrome

Li, F. P., & Fraumeni, J. F. (1969) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/43.6.1365 · Cited by 397 · see citing works

MDM2, an introduction.

Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 390 · see citing works

TP53 mutation in colorectal cancer

Iacopetta, B. J. (2003) · Human Mutation · doi:10.1002/humu.10175 · Cited by 345 · see citing works

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · see citing works

ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors

Zaika, A., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M. L., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 316 · see citing works

Genetic background alters the spectrum of tumors that develop in p53‐deficient mice

Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285 · see citing works

Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes

Fusenig, N. E., & Boukamp, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199811)23:3 · Cited by 282 · see citing works

Effects of genetic background on tumorigenesis in <i>p53</i>‐deficient mice

Donehower, L. A., Harvey, M., Vogel, H., McArthur, M. J., Montgomery, C. A., Park, S. H., Thompson, T., Ford, R. J., & Bradley, A. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940140105 · Cited by 252 · see citing works

Tumor Suppressor p53: Analysis of Wild-Type and Mutant p53 Complexes

Milner, J., Medcalf, E., & Cook, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243 · see citing works

Germline p53 Mutations in a Cohort with Childhood Sarcoma: Sex Differences in Cancer Risk

Hwang, S., Lozano, G., Amos, C. I., & Strong, L. C. (2003) · The American Journal of Human Genetics · doi:10.1086/374567 · Cited by 229 · see citing works

Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities

Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Sal, G. D., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 225 · see citing works

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. T. M., Sage, J., & Jacks, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713099 · Cited by 207 · see citing works

TP53 family members and human cancers

Bénard, J., Douc‐Rasy, S., & Ahomadegbe, J. (2003) · Human Mutation · doi:10.1002/humu.10172 · Cited by 205 · see citing works

High metastatic potential in mice inheriting a targeted p53 missense mutation

Liu, G., McDonnell, T. J., Luna, R. M. D. O., Kapoor, M., Mims, B. H., El‐Naggar, A. K., & Lozano, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4174 · Cited by 198 · see citing works

Activation of c- myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain

Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194 · see citing works

A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.

Stürzbecher, H. W., Brain, R., Addison, C. M., Rudge, K., Remm, M., Grimaldi, M., Keenan, E., & Jenkins, J. R. (1992) · PubMed · Cited by 191 · see citing works

Rhabdomyosarcoma in Children

Pinkel, D. P. (1961) · JAMA · doi:10.1001/jama.1961.03040040025005 · Cited by 183 · see citing works

Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.

Ishimoto, O., Kawahara, C., Enjo, K., Obinata, M., Nukiwa, T., & Ikawa, S. (2002) · PubMed · Cited by 177 · see citing works

Transactivation-deficient ΔTA-p73 Inhibits p53 by Direct Competition for DNA Binding

Stiewe, T., Theseling, C. C., & Pützer, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200480200 · Cited by 173 · see citing works

Tumor Radiosensitivity and Apoptosis

Zhivotovsky, B., Joseph, B., & Orrenius, S. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4452 · Cited by 148 · see citing works

An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2

Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138 · see citing works

Transdominant ΔTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo

Concin, N., Becker, K., Slade, N., Erster, S. H., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A. G., Zeillinger, R., Marth, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1060 · Cited by 138 · see citing works

Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53

Filippovitch, I., Sorokina, N., Gatei, M. H., Haupt, Y., Hobson, K., Moallem, E., Spring, K. J., Mould, M. A., McGuckin, M. A., Lavin, M. F., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204118 · Cited by 121 · see citing works

Tumor radiosensitivity and apoptosis

Guang, Z. (2000) · Cited by 121 · see citing works

The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.

Slingerland, J., Jenkins, J. R., & Benchimol, S. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05744.x · Cited by 105 · see citing works

The Li–Fraumeni syndrome

Chompret, A. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01361-x · Cited by 99 · see citing works

Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil

Pugacheva, E. N., Ivanov, A. V., Kravchenko, J. E., Kopnin, B. P., Levine, A. J., & Chumakov, P. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205704 · Cited by 99 · see citing works

A transgenic mouse model for mammary carcinogenesis

Li, B., Murphy, K. L., Laucirica, R., Kittrell, F. S., Medina, D., & Rosen, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201621 · Cited by 89 · see citing works

Drug discovery and p53

Lane, D. P., & Hupp, T. R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02669-2 · Cited by 85 · see citing works

Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis

Wang, X., Greenhalgh, D. A., Jiang, A., He, D., Zhong, L., Medina, D., Brinkley, B. R., & Roop, D. R. (1998) · Oncogene · doi:10.1038/sj.onc.1201890 · Cited by 85 · see citing works

p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.

Skaug, V., Ryberg, D., Kure, E. H., Arab, M. O., Stangeland, L. B., Myking, A. O., & Haugen, A. (2000) · PubMed · Cited by 85 · see citing works

The Li-Fraumeni syndrome: An inherited susceptibility to cancer

Evans, S. C., & Lozano, G. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01105-2 · Cited by 82 · see citing works

p53 Gene Status Modulates the Chemosensitivity of Non-Small Cell Lung Cancer Cells

Lai, S., Perng, R.-P., & Hwang, J. (2000) · Journal of Biomedical Science · doi:10.1007/bf02255920 · Cited by 79 · see citing works

Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.

Powell, B. L., Soong, R., Iacopetta, B. J., Seshadri, R., & Smith, D. R. (2000) · PubMed · Cited by 73 · see citing works

p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1

Asher, G., Lotem, J., Tsvetkov, P., Reiss, V., Sachs, L., & Shaul, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436329100 · Cited by 70 · see citing works

Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer

Bataille, F., Rümmele, P., Dietmaier, W., Gaag, D., Klebl, F., Reichle, A., Wild, P. J., Hofstädter, F., & Hartmann, A. (2003) · Molecular Pathology · doi:10.1136/mp.56.5.286 · Cited by 45 · see citing works

Rhabdomyosarcoma in Children

Hawkins, H. K., & Camacho-Velasquez, J. V. (1987) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198707000-00005 · Cited by 32 · see citing works

p53 mutations and resistance to chemotherapy: A stab in the back for p73

Soussi, T. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00081-3 · Cited by 28 · see citing works

Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice

Iwakuma, T., Parant, J. M., Fasulo, M., Zwart, E., Jacks, T., de Vries, A., & Lozano, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207793 · Cited by 26 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

p53 mutations in cancer

Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647 · see citing works

Impact of mutant p53 functional properties on <i>TP53</i> mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · see citing works

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression

Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286 · see citing works

When mutants gain new powers: News from the mutant p53 field

Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

p53 and metabolism

Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · see citing works

p53 ubiquitination: Mdm2 and beyond

Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

Mutant p53 drives invasion by promoting integrin recycling

Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796 · see citing works

Revisiting Li-Fraumeni Syndrome From <i>TP53</i> Mutation Carriers

Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760 · see citing works

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648 · see citing works

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615 · see citing works

Mutational processes shape the landscape of TP53 mutations in human cancer

Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556 · see citing works

The Differential Effects of Mutant <i>p53</i> Alleles on Advanced Murine Lung Cancer

Jackson, E. L., Olive, K. P., Tuveson, D. A., Bronson, R., Crowley, D., Brown, M., & Jacks, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2193 · Cited by 553 · see citing works

Gain of function of mutant p53 by coaggregation with multiple tumor suppressors

Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543 · see citing works

Proteogenomic Characterization of Endometrial Carcinoma

Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485 · see citing works

Genetically engineered mouse models in oncology research and cancer medicine

Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502 · see citing works

Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493 · see citing works

p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug

Wang, S.-P., Wang, W.-L., Chang, Y.-L., Wu, C.-T., Chao, Y.-C., Kao, S.-H., Yuan, A., Lin, C.-W., Yang, S.-C., Chan, W.-K., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1875 · Cited by 493 · see citing works

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · see citing works

p53 and its mutants in tumor cell migration and invasion

Muller, P. A. J., Vousden, K. H., & Norman, J. C. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009059 · Cited by 463 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis

Masaldan, S., Clatworthy, S. A. S., Gamell, C., Meggyesy, P. M., Rigopoulos, A.-T., Haupt, S., Haupt, Y., Denoyer, D., Adlard, P. A., Bush, A. I., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2017.08.015 · Cited by 452 · see citing works

Tumour-associated mutant p53 drives the Warburg effect

Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · see citing works

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

Kadosh, E., Snir-Alkalay, I., Venkatachalam, A., May, S., Lasry, A., Elyada, E., Zinger, A., Shaham, M., Vaalani, G., Mernberger, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2541-0 · Cited by 378 · see citing works

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

Maser, R. S., Choudhury, B., Campbell, P. J., Feng, B., Wong, K.-K., Protopopov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007) · Nature · doi:10.1038/nature05886 · Cited by 377 · see citing works

The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

Manfredi, J. J. (2010) · Genes &amp; Development · doi:10.1101/gad.1941710 · Cited by 344 · see citing works

p53-Mediated Hematopoietic Stem and Progenitor Cell Competition

Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342 · see citing works

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336 · see citing works

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329 · see citing works

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308 · see citing works

The p53 family in differentiation and tumorigenesis

Stiewe, T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2072 · Cited by 306 · see citing works

Trim24 targets endogenous p53 for degradation

Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292 · see citing works

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner

Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287 · see citing works

Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer

Tucci, P., Agostini, M., Grespi, F., Markert, E. K., Terrinoni, A., Vousden, K. H., Muller, P. A. J., Dötsch, V., Kehrloesser, S., Sayan, B. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110977109 · Cited by 286 · see citing works

Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines

Liu, Y., & Bodmer, W. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510146103 · Cited by 257 · see citing works

Smoking, p53 Mutation, and Lung Cancer

Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255 · see citing works

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243 · see citing works

Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer

Walerych, D., Lisek, K., Sommaggio, R., Piazza, S., Ciani, Y., Dalla, E., Rajkowska, K., Gaweda-Walerych, K., Ingallina, E., Tonelli, C., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3380 · Cited by 239 · see citing works

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families

Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230 · see citing works

Links between mutant p53 and genomic instability

Hanel, W., & Moll, U. M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23400 · Cited by 216 · see citing works

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163 · see citing works

The role of tumor suppressor p53 in the antioxidant defense and metabolism

Budanov, A. V. (2014) · Subcellular Biochemistry · doi:10.1007/978-94-017-9211-0_18 · Cited by 157 · see citing works

Osteosarcoma: Molecular Pathogenesis and iPSC Modeling

Lin, Y.-H., Jewell, B. E., Gingold, J., Lu, L., Zhao, R., Wang, L. L., & Lee, D.-F. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.06.004 · Cited by 150 · see citing works

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134 · see citing works

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129 · see citing works

A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127 · see citing works

Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities

Kollareddy, M., Dimitrova, E., Vallabhaneni, K. C., Chan, A., Le, T., Chauhan, K. M., Carrero, Z. I., Ramakrishnan, G., Watabe, K., Haupt, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms8389 · Cited by 127 · see citing works

Cell of origin influences pancreatic cancer subtype

Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118 · see citing works

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5

Vogiatzi, F., Brandt, D. T., Schneikert, J., Fuchs, J., Grikscheit, K., Wanzel, M., Pavlakis, E., Charles, J. P., Timofeev, O., Nist, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612711114 · Cited by 99 · see citing works

Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome

Colla, S., Ong, D. S. T., Ogoti, Y., Marchesini, M., Mistry, N. A., Clise-Dwyer, K., Ang, S. A., Storti, P., Viale, A., Giuliani, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.007 · Cited by 105 · see citing works

p53 at the crossroads between cancer and neurodegeneration

Lanni, C., Racchi, M., Memo, M., Govoni, S., & Uberti, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.034 · Cited by 95 · see citing works

Towards an understanding of the role of p53 in adrenocortical carcinogenesis

Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84 · see citing works

HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis

Ryu, H.-W., Shin, D.-H., Lee, D. H., Choi, J., Han, G., Lee, K. Y., & Kwon, S. H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.033 · Cited by 82 · see citing works

The Mdm network and its regulation of p53 activities: a rheostat of cancer risk

Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79 · see citing works

Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells

Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74 · see citing works

Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist

Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75 · see citing works

p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant

Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer &amp; Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58 · see citing works

Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo

Lambrecht, C., Libbrecht, L., Sagaert, X., Pauwels, P., Hoorne, Y., Crowther, J., Louis, J. V., Sents, W., Sablina, A., & Janssens, V (2018) · Oncogene · doi:10.1038/onc.2017.350 · Cited by 50 · see citing works

Therapeutic Efficacy of <i>p53</i> Restoration in <i>Mdm2</i> -Overexpressing Tumors

Li, Q., Zhang, Y., El-Naggar, A. K., Xiong, S., Yang, P., Jackson, J. G., Chau, G., & Lozano, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0089 · Cited by 30 · see citing works

Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse

Guo, X., Liu, Y., Kim, J. L., Kim, E. Y., Kim, E. Q., Jansen, A., Li, K., Chan, M., Keenan, B. T., Conejo-Garcia, J., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212930 · Cited by 23 · see citing works

What do we need to know and understand about p53 to improve its clinical value?

Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15 · see citing works

Are <i>TP53</i> mutations all alike?

Wong, T. N., & Link, D. C. (2024) · Hematology · doi:10.1182/hematology.2024000556 · Cited by 11 · see citing works

Oncogenes and tumor suppressor genes.

Weinberg, R. A. (1988) · PubMed

THE SIGNIFICANCE OF TUMOR SUPRESSOR GENES INACTIVATION IN CARCINOGENESIS OF MULTIPLE PRIMARY NEOPLASM

Ju, J. (2000) · Chinese Journal of Bases and Clincs In General Surgery

[Tumor suppressor gene: implication in the clinical medicine].

Takai, S., Tanaka, N., Shin, E., et al. (1990) · PubMed · Cited by 1 · see citing works

Inactivation of X-Linked Tumor Suppressor Genes in Human Cancer

Liu, R., Kain, M., & Wang, L. (2012) · Future Oncology · doi:10.2217/fon.12.26 · Cited by 34 · see citing works

Tumor Suppressor Genes: The Puzzle and the Promise

Sager, R. (1989) · Science · doi:10.1126/science.2574499 · Cited by 477 · see citing works